E-LIB Suche - Ergebnisse für: Loftus Jr., E

1

P271 Evolving Targets in Ulcerative colitis: Defining Disea..:

Danese, S ; Schreiber, S ; Loftus Jr., E...
Journal of Crohn's and Colitis. 15 (2021) Supplement_1 - p. S305-S305 , 2021

Link: https://doi.org/10.1093/..

2

P669 Adalimumab long-term effectiveness in adalimumab-naïve..:

Loftus Jr., E. ; D'Haens, G. ; Reinisch, W....
Journal of Crohn's and Colitis. 11 (2017) suppl_1 - p. S422-S423 , 2017

Link: https://doi.org/10.1093/..

3

PYRAMID Registry:

D'Haens, G ; Reinisch, W ; Satsangi, J...
Inflammatory Bowel Diseases. 17 (2011) suppl_1 - p. S44-S45 , 2011

Link: https://doi.org/10.1093/..

4

Markov model projection of remission status for early vs. d..:

Loftus Jr, E ; Chao, J ; Yang, M...
Inflammatory Bowel Diseases. 17 (2011) suppl_1 - p. S52-S53 , 2011

Link: https://doi.org/10.1093/..

5

Treatment adjustment indicators in patients with crohn's di..:

Loftus Jr, E ; Yang, M ; Laitinen, D...
Inflammatory Bowel Diseases. 17 (2011) suppl_1 - p. S7-S7 , 2011

Link: https://doi.org/10.1093/..

6

Primary intestinal Lymphoma in patients with Inflammatory B..:

Holubar, S ; Dozois, E ; Loftus Jr., E...
Inflammatory Bowel Diseases. 15 (2009) - p. S21-S22 , 2009

Link: https://doi.org/10.1097/..

7

Patterns and predictors of dosage increase in patients trea..:

Loftus Jr, E ; Pan, X ; Zurawski, P..
Inflammatory Bowel Diseases. 15 (2009) - p. S24 , 2009

Link: https://doi.org/10.1097/..

8

Adalimumab Therapy maintains steroid-free remission and Fis..:

Panaccione, R ; Loftus Jr, E ; Binion, D...
Inflammatory Bowel Diseases. 15 (2009) - p. S43 , 2009

Link: https://doi.org/10.1097/..

9

Impact of Adalimumab on Hospitalization Risk for TNF-Antago..:

Loftus Jr, E ; Feagan, B ; Colombel, J...
Inflammatory Bowel Diseases. 14 (2008) - p. S1 , 2008

Link: https://doi.org/10.1097/..

10

Adalimumab maintenance therapy for patients with Crohn's Di..:

Feagan, B ; Loftus Jr, E ; Johnson, S...
Inflammatory Bowel Diseases. 14 (2008) - p. S33 , 2008

Link: https://doi.org/10.1097/..

11

P678 Long-term efficacy, safety and health-related quality ..:

Feagan Senior Scientific Officer, B G ; Matsuoka, K ; Rogler, G...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1288-i1289 , 2024

Link: https://doi.org/10.1093/..

12

P540 Non-serious adverse events in patients with ulcerative..:

Lees, C ; Torres, J ; Leung, Y...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1062-i1064 , 2024

Link: https://doi.org/10.1093/..

13

P734 Super-responders in patients with moderate-to-severe C..:

Schreiber, S W ; Sands, B E ; Hanauer, S B...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1375-i1376 , 2024

Link: https://doi.org/10.1093/..

14

P862 Effects of induction and maintenance therapy with risa..:

Panés, J ; Loftus Jr., E V ; Armuzzi, A...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1596-i1597 , 2024

Link: https://doi.org/10.1093/..

15

OP10 Efficacy and safety of upadacitinib in patients with m..:

D'Haens, G ; Louis, E ; Loftus Jr., E V...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i17-i18 , 2024

Link: https://doi.org/10.1093/..